Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

• Status: Terminated
• Trial end date: 2014-07-01

Summary

To determine if oral antibiotic treatment with CEM-102 and Rifampin is as effective and safe as the standard of care antibiotic therapy for the treatment of hip and knee prosthetic joint or spacer infections

• Phase: Phase 2

Details

• Lead Sponsor: Arrevus Inc.; Cempra Inc
• Treatments: Anti-Bacterial Agents; Cefazolin; Ceftriaxone; Ciprofloxacin; Daptomycin; Fusidic Acid; Levofloxacin; Linezolid; Nafcillin; Oxacillin; Rifampin; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin